276. 軟骨無形成症 Achondroplasia Clinical trials / Disease details

臨床試験数 : 51 /  薬物数 : 34 - (DrugBank : 6) / 標的遺伝子数 : 4 - 標的パスウェイ数 : 26

  
2 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2019-002954-21-FR
(EUCTR)		06/05/202020/01/2020A study to evaluate Infigratinib in children with AchondroplasiaPhase 2, Open-Label, Dose-Escalation and Dose-Expansion Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children with Achondroplasia: PROPEL 2 - PROPEL 2 Achondroplasia in Children
MedDRA version: 20.0;Level: LLT;Classification code 10000452;Term: Achondroplasia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]		Product Name: Infigratinib phosphate
Product Code: BGJ398 (also known as BBP-831)
INN or Proposed INN: INFIGRATINIB		QED Therapeutics, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		60Phase 2United States;France;Canada;Spain;Australia;United Kingdom
2EUCTR2019-002954-21-GB
(EUCTR)		31/03/202013/05/2020A study to evaluate Infigratinib in children with AchondroplasiaPhase 2, Open-Label, Dose-Escalation and Dose-Expansion Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children with Achondroplasia: PROPEL 2 - PROPEL 2 Achondroplasia in Children
MedDRA version: 20.0;Level: LLT;Classification code 10000452;Term: Achondroplasia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]		Product Name: Infigratinib phosphate
Product Code: BGJ398 (also known as BBP-831)
INN or Proposed INN: INFIGRATINIB		QED Therapeutics, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		78Phase 2United States;France;Canada;Spain;Australia;United Kingdom